

## About the Editors

**Dr. Hugh Smyth** is an Assistant Professor of Pharmaceutics at the University of Texas, Austin. He is a recipient of the Young Investigator in Pharmaceutics and Pharmaceutical Technology Award of the American Association of Pharmaceutical Scientists and has published in many different aspects of pulmonary drug delivery. Drs. Hickey and Smyth share a research interest in the delivery of drugs to the lungs for the treatment and prevention of a number of diseases.

**Dr. Anthony Hickey** is a Professor of Molecular Pharmaceutics and Biomedical Engineering at the University of North Carolina at Chapel Hill. He is a fellow of the Institute of Biology, American Association of Pharmaceutical Scientists and the American Association for the Advancement of Science. He has published several edited and authored volumes in the fields of pharmaceutical aerosols, process engineering and particulate science.

# Index

## A

Abbreviated impactor measurement (AIM)  
concept, 388–392

ABC-transporters, 425–426

Acorn II® jet nebulizer. *See* Jet nebulizers

Active DPIs, 205

Adaptive aerosol delivery nebulizers, 230

Aerodynamic diameter

DPI formulations, 206

low density porous particles, 94

lung disposition, 128

mucociliary escalator, 106

nanodisperse microspheres, 349

nebulizer, 230

particle engineering, 286–288

Aerodynamic particle size distribution (APSD)

cascade impactors, 383

CCS components, MDIs, 493, 501

in vitro equivalence, 515

Aerohaler, 69

Aeroneb Pro® vibrating mesh nebulizer, 229

Aerosol administration methods

direct administration, 457–459

passive inhalation, 454–457

Aerosol delivery

particle deposition mechanisms, 5

targeted anatomical sites, 4–5

Aerosol drug inhalation, 492–493

Aerosol electrostatics

direct measurement

ELPI, 394–395

eNGI, 395–396

dynamic systems, Faraday cage method,  
393–394

indirect measurement, 396–398

triboelectrification, 392–393

Aerosolization systems

inhaler technology

aerosol, 75

categories, delivery system, 76

nebulizer, pMDIs and DPIs, 76, 77

particle engineering technologies

milling, 78

spray drying, 79

powders

drug aerosolization, 91–92

drug deposition, 92–94

elongated particles, 95

low density porous particles, 94

mixing, 89–91

particulate interactions, 87–89

sprays

droplet formation, 81–86

evaporation, 86

solution/suspension formulation, 80–81

suspension aerosols aggregation, 86–87

Aerosol particle deposition

influencing factors

mode of inhalation, 5–6

obstructive diseases, 7–8

oropharyngeal morphology, 6–7

mechanisms, 5

Aerosol particle transport

diffusion

enhancement methods, 157–158

vs. hydrodynamic diameter, 154

measurement methods, 155–157

mucus network, 153–154

PEG coating, 157–158

Stokes–Einstein equation,  
152–153

drug retention time, 144

- Aerosol particle deposition (*cont.*)  
 mucociliary escalator  
 histology, airway epithelial culture, 149–150  
 mucolytic agents, 150–151  
 physicochemical properties, 151–152  
 submersion  
 conducting airways, physical properties, 148  
 limitations, 149  
 particle wetting, 147  
 process, Young equation, 146–147  
*in vivo* animal studies, 146  
 surface spreading  
 surface tension, 144–145  
 surfactant, 145  
 therapeutic delivery *vs.* traditional drug delivery, 143
- Aerosol submersion process  
 conducting airways, physical properties, 148  
 limitations, 149  
 particle wetting, 147  
 process, Young equation, 146–147  
*in vivo* animal studies, 146
- AFM. *See* Atomic force microscopy (AFM)
- AFM colloid probe technique, 400–403
- Air-jet nebulizer, 81
- Airways  
 aerosol delivery  
 particle deposition mechanisms, 5  
 targeted anatomical sites, 4–5  
 alveolar cells, 9–10  
 $\beta$  adrenergic receptors, 10  
 basal cells, 9  
 binding affinities, corticosteroids, 11  
 blood flow, 12–14  
 cell type and regional thickness, 4  
 ciliated columnar cells, 9  
 clara cells, 9  
 conducting zone  
 damages, dry gas inspiration, 3  
 function, 2  
 influencing factors, lung deposition, 2  
 endothelin receptors, 11  
 glucocorticoid receptors (GR), 11  
 goblet and mast cells, 9  
 prostacyclin receptor (PR) agonists, 12  
 respiratory zone, 3–4  
 secretions, 14–15  
 selectivity and duration of effect, 38–41  
 smooth muscle cells, 9  
 structure, 447–449
- Albumin, 135–137, 268
- Alveolar epithelial cell lines (AEC)  
 absorption, 421–422  
 A549 cell line, 421  
 continuous cell cultures, 421–423  
 immortalised cell lines, 421  
 L–2 cells, 422  
 MLE cell lines, 422  
 P-glycoprotein, 425–426  
 primary cell cultures, 418–419  
 proteolytic enzymes, 422–423  
 transepithelial electrical resistance (TEER), 421  
 vitamin C, 432
- Alveolar macrophage clearance, 27, 104  
 avoidance, 114–120  
 morphometric parameters, 449  
*in vivo* animal models, 444
- Alveolar macrophages (AM), 326
- Amorphous sugars  
 controlled release function, 256  
 trehalose microparticles and insulin releases, 256, 257
- Andersen cascade impactor (ACI), 385–387
- Antisense oligodeoxynucleotide (AS-ODN)  
 delivery, 329
- APSD. *See* Aerodynamic particle size distribution (APSD)
- Aradigm AerX™ aerosol. *See* metered dose liquid inhalers (MDLI)
- Asthma  
 cigarettes, 63  
 inhalation drug products  
 controller drugs, 509  
 definition, 507  
 medication groups, 508  
 reliever drugs, 508  
 powders, 63
- Atomic force microscopy (AFM) method, 398–399
- Atomizers. *See* Jet nebulizers
- ATP-binding cassette (ABC) transporters, 133–134
- Atropine, 67
- B**
- Bennet's inhaler, 53
- Bergson tubes, 57–58
- Bioerodable nanoparticles, 358–360
- Biological and macromolecule degradation, 120–121
- Bovine serum albumin (BSA) microspheres.  
*See* Albumin
- Bronchoalveolar lavage fluid (BAL), 317

Broncho alveolar lavage fluid (BALF), 328  
Budesonide formulation, 342, 343

## C

Camptothecin therapy, 325

### Cancer

- camptothecin therapy, 325
- cisplatin SLIT and paclitaxel therapy, 324, 325
- interleukin-2 (IL-2) therapy, 324
- liposome-encapsulated 9-NC (L-9NC) therapy, 325
- sustained release lipid inhalation targeting (SLIT), 324
- transferrin receptors (TfR), 325, 326

Carrageenan, 268–269

Cascade impactors (CIs)

- Andersen cascade impactor (ACI), 385–387
- APSD measurement, 383–384
- development considerations, 387
- multistage cascade impactor, schematic diagram, 385
- simplification
  - AIM concept, 388–392
  - EDA metrics, 387–388
  - single-stage inertial impactor, 384–385

CCS. *See* Container closure systems (CCS)

CD. *See* Cyclodextrins (CD)

Chitosan, 269–270. *See also* Polyplex-mediated transfection

Chronic obstructive pulmonary disease (COPD)

- aerosol particle deposition, 7
- in vivo evaluations, inhaled respiratory drugs, 507, 509–510

Ciprofloxacin, 268, 322

Cisplatin SLIT, 324, 325

Cohesive–adhesive balance (CAB)

- measurement method, 403

Combustion-derived nanoparticles (CDNP), 356–357

Compendial methods. *See* Cascade impactors

Conducting airways

- cells, 9
- damages, dry gas inspiration, 3
- function, 2
- influencing factors, lung deposition, 2

Conjugate excipients

- controlled release function, 248
- definition, 244
- dextran, 248–249
- PEGylation, 249

Container closure systems (CCS), 498–502

COPD. *See* Chronic obstructive pulmonary disease (COPD)

Copolymers, 248

Cosolvents, HFA-based formulations, 172–173

Cyclodextrins (CD)

- base structures, 250
- chemical structures, 251
- controlled release function
  - CDs alone, 253
  - mechanism, 252
  - with PLGA, 255
- types use, pharmaceutical formulations, 250, 251

Cystic fibrosis (CF) model, 423

## D

Dextran, 248–249

Diffusional transport

- enhancement methods, 157–158
- vs. hydrodynamic diameter, 154
- measurement methods
  - diffusion chambers, 155
  - single particle tracking, 155–157
- mucus network, 153–154
- PEG coating, 157–158
- Stokes–Einstein equation, 152–153

Dipalmitoylphosphatidylcholine (DPPC), 316

Direct controlled crystallization, 298–299

Disease models. *See* Cystic fibrosis (CF) model

Disease prevention therapy, plasmid DNA advantages, 374–375

principles, vaccination

- advantages, 373
- vs. gene therapy, 372
- potential barriers, 373, 374

transport into lung

- intracellular barriers gene therapy, 370, 376
- studies, overview of, 376
- in vitro* and *in vivo* immunogenicity, 376

Diskhaler, 71

DissoCubes™ technology, 293

Dissolution kinetics, 22–24

Dose calculation, *in vivo* animal models

- aerosol administration, 454
- drug deposition assessment, 459–460
- pharmacokinetics models, drug disposition, 461–462
- pulmonary bioavailability, 463–464
- quantification, drug concentrations, 460–461
- rate of absorption, 463–464

Doxorubicin, 350

- DPIs. *See* Dry powder inhalers (DPIs)
- Droplet formation
- nebulizer
    - count median diameter (CMD), 82
    - droplet size, 82–83
    - efficiency, 84
    - mass output rate, 84
    - primary droplet diameter ( $d$ ), 82, 83
    - vibrating-mesh, 82
  - pMDI
    - critical bubble radius ( $R_c$ ), 85
    - droplet diameter ( $D_d$ ), 85
    - Rayleigh-Taylor instability, 86
    - velocity droplet function time, 85
- Drug absorption avoidance
- considerations, in vivo animal models, 452
  - formulations
    - liposomes, 110–111
    - microparticles, 111–112
    - PEGylation, 113
    - prodrugs, 113
  - structural modification, 109
- Drug aerosolization, 91–92
- Drug deposition, 92–94
- Drug diffusion, polymer system, 266
- Drug formulations
- liposomes, 110–111
  - microparticles, 111–112
  - PEGylation, 113
  - prodrugs, 113
- Drug solubility screening, propellants
- online reversed-phase HPLC system, 405
  - in situ method, 404–405
- Drug transporters, 32–34
- Dry powder inhalers (DPIs)
- advantages, 205
  - aerosolization systems, 76, 77
  - challenge, 207
  - computational fluid dynamics (CFD), 207
  - development (*see* Powder de-agglomeration principles, DPI)
  - device classification, 205
  - Exubera®, 207
  - formulating factors, liposomes, 318
  - formulations, 205–206
  - inhalation drug products, 493–494
  - inter-particulate interaction methods
    - AFM colloid probe technique, 400–403
    - CAB measurement, 403
  - limitations, 205
  - manufacturing process
    - aerosolization, 218
    - blenders, 217–218
    - device design, 219
    - micronization, 217
    - primary manufacture, 217
  - nebulizers, 204
  - Newton's patent, 61
  - objectives, 203–204
  - particle engineering technologies, 289–290
  - passive device, 205
  - performance, 204
  - pMDIs, 204
  - vs. pMDIs, 166
  - powder de-agglomeration principles
    - air classifier technology, 211–212
    - device resistance and flow rate, 214–215
    - mechanical forces, 208–209
    - meshes and screens, 215–216
    - Novolizer™, 212
    - sustained exposure, flow stream, 210–212
    - turbulence inducement, 207–208
    - Twincer™, 212
    - vibration induced dispersion, 212–214
  - pulmonary delivery strategies
    - aggregated nanoparticles, 352–354
    - AIR® technology, 355
    - nanodisperse microspheres, 349–352
    - vs. nebulized dispersions, 349
    - PulmoSphere® technology, 354–355
    - rapid freezing technology, 355
  - regions, device, 207
- E**
- Efficient Data Analysis concept, 387–388
- Electrical low pressure impactor (ELPI), 394–395
- Electrical next generation impactor (eNGI), 395–396
- EPAS. *See* Evaporative precipitation into aqueous solution process (EPAS)
- E-SPART analyzer, 396–398
- Evaporative precipitation into aqueous solution process (EPAS), 300–301
- Excipients
- amorphous sugars, 257
  - CD
    - base structures, 250
    - chemical structures, 251
    - controlled release function, 252–255
    - types use, pharmaceutical formulations, 250, 251
  - conjugate excipients
    - controlled release function, 248
    - definition, 244

- dextran, 248–249
  - PEGylation, 249
  - definition, 237
  - findings, sustained release, 238
  - glass transition temperature (T<sub>g</sub>), 256
  - HFA-based formulations, pMDIs, 172
  - inhalation drug products, 496–497
  - liposomes
    - half-lives, liposome-encapsulated
      - <sup>3</sup>H-terbutaline, 242, 243
    - pharmacokinetics, 240–241
    - phospholipids, chemical structure, 238
    - rate of release, 239
    - vs. solution formulations, 239–242
  - microcrystals, 257–258
  - polymers
    - copolymers, 248
    - definition, 243
    - mechanisms, controlled release, 244
    - natural and synthetic types, 243, 245–247
  - suspensions, 258
- F**
- Faraday cage method, 393–394
  - Fine particle fraction (FPF), 288
  - Flow-through cell system, 406–407
  - Fluid energy milling technology, 291–292
  - Food and Drug Administration (FDA), 489
  - FPF. *See* Fine particle fraction (FPF)
  - Fumaryl diketopiperazine (FDKP), 354
- G**
- Gamma imaging. *See* Imaging
  - Gamma scintigraphy
    - clinical gamma camera, 476–477
    - image acquisitions types, 477–478
    - SPECT image acquisition, 478
  - Gelatin, 270–271
  - Generic inhalation drug products
    - equivalent systemic exposure, 516–517
    - local equivalent, 517–519
    - Q<sub>1</sub> & Q<sub>2</sub> sameness, 515
    - safety and efficacy, BE studies, 514
    - in vitro* equivalence, 515
    - Weight of Evidence approach, 514–515
- H**
- Henbane, 51
  - 2H,3H-perfluoropentane (HPFP), 170
  - High pressure homogenization
    - microfluidizer, 292–293
    - piston-gap, 293–294
    - uses, 292
- History**
- emerging themes, 72
  - henbane, 51
  - native smoking pipes, 52
  - nineteenth century
    - advertisements, inhalers, 64–65
    - asthma powders and cigarettes, 63
    - Bergson tubes, 57–58
    - Carbolic Smoke Ball advertisement, 66
    - Dr. Worst's inhaler advertisement, 66
    - Humphrey's inhaler, 56
    - Nelson inhaler, 62
    - Newton's patent, dry powder inhaler, 61
    - Sales-Girons' portable atomiser, 57–58
    - Siegle's inhaler, 59
  - seventeenth and eighteenth centuries
    - Bennet's inhaler, 53
    - Mudge inhaler, 54–55
    - Stern inhaler, 54
  - twentieth century
    - aerohalor, 69
    - atropine, 67
    - Maxim's pipe of peace, 67
    - MediHaler advertisement, 70
    - Pneumostat electric compressor nebulizer, 68
    - rotahaler and turbuhaler, 71
    - spinhaler and diskhaler, 71
- Humphrey's inhaler, 56
- Hyaluronic acid (HA), 119, 271–272
- Hydrofluoroalkane (HFA)-based formulations, pMDIs
- cosolvents, 172–173
  - excipients, 172
  - particle technologies, 188–190
  - solubility and solvation
    - atomic force microscopy, 183–185
    - binding energy, 181
    - electrostatic or dispersive forces, 183
    - ester-based polymers, 178
    - excipients and APIs, 175–177
    - modeling, 174
    - polarity, fragment, 180, 182
    - rational surfactant design, 186–188
    - shape, fragment, 182
    - solvation forces, 183–186
    - surfactants, 174, 178–179
  - solubility enhancers, 172–173
  - solute solubility, 174–179
- Hydroxypropyl- $\beta$ -cyclodextrin (HPBC), 189

**I**

Iloprost, 327

**Imaging**

- dose administration, 480–481
- gamma scintigraphy
  - clinical gamma camera, 476–477
  - image acquisitions types, 477–478
  - SPECT image acquisition, 478

**image acquisition**

- planar image acquisition, 482
- SPECT image acquisition, 483
- subject coaching and subject positioning, 481

**image analysis**

- central and peripheral lung regions, 482, 484
- lung regional deposition, 485

**radiolabeling aerosols**

- inhalation deposition analysis, 478–479
- validation process, 479–480

**Inhalation deposition analysis****imaging**

- dose administration, 480–481
- gamma scintigraphy, 476–478
- image acquisition, 481–483
- image analysis, 483–485
- radiolabeling aerosols, 478–480
- radiolabeling aerosols, 478–480
- radiolabeling validation, 479–480
- in vitro* testing, 475–476

**Inhalation drug products**

- combination products, 511–512
- extended-release dosage forms, 512–513
- FD&C Act, 489–490
- generic drug products
  - equivalent systemic exposure, 516–517
  - local equivalent, 517–519
  - $Q_1$  &  $Q_2$  sameness, 515
  - safety and efficacy, BE studies, 514
  - in vitro* equivalence, 515
  - Weight of Evidence approach, 514–515

**manufacturing and controls**

- DPIs, 493–494
- drug substances, 496
- excipients, 496–497
- MDIs, 492–493
- solutions and suspensions, 495
- sprays, 495–496

**NDA, 490**

- new drug development and approval process, 489–490

- reference listed drug products (RLDs), 490, 514, 518

**in vitro evaluations**

- plume geometry, 503–504
- PSD, 503
- spray pattern, 503–504

**in vivo evaluations**

- asthma, 507–509
- clinical development program, 505–507
- COPD, 509–510
- nonclinical testing, 504–505
- safety considerations, 495

- Inhaled particle–respiratory fluid interactions. *See* Aerosol particle transport

- Insulin liposomes, 318

- Interleukin-2 (IL-2) therapy, 324

***In vitro* cell culture models**

- alveolar epithelial cell lines (*see* Alveolar epithelial cell lines)

- co-culture models, 424

**continuous cell cultures**

- alveolar epithelial cell lines, 421–423
- disadvantages, 419
- vs. primary cell cultures, 419
- tracheobronchial epithelial cell lines, 419–421

- cystic fibrosis (CF), 423

**drug absorption studies**

- alveolar epithelial cells, 430–433
- tracheo-bronchial epithelial cells, 425–430

**particle impingement studies**

- multistage liquid impinger (MSLI), 433
- twin-stage impinger (TSI), 433–434

**primary cell cultures**

- alveolar epithelia, 418–419
- tracheo-bronchial epithelia, 418

- tracheo-bronchial epithelial cells (*see* Tracheo-bronchial epithelial cells)

***In vitro* performance testing****aerosol electrostatics**

- direct measurement, 394–396
- dynamic systems, Faraday cage method, 393–394
- indirect measurement, 396–398
- triboelectrification, 392–393

**cascade impactors (CIs)**

- Andersen cascade impactor (ACI), 385–387

- APSD measurement, 383–384

- development considerations, 387

- multistage cascade impactor, schematic diagram, 385

- simplification, 387–392

- single-stage inertial impactor, 384–385

- static characterization methods
    - drug solubility screening, propellants, 404–405
    - inter-particulate interaction, DPI, 400–403
    - surface morphology, 398–400
  - in vitro* dissolution studies
    - dissolution medium, 410–411
    - experimental difficulties, 406
    - flow-through cell, 406–407
    - ideal test procedure, 405–406
    - membrane holder, 407–409
  - In vivo* animal models
    - disease models, 464–467
    - dose calculation
      - aerosol administration, 454–459
      - drug deposition assessment, 459–460
      - pharmacokinetics models, drug disposition, 461–462
      - pulmonary bioavailability, 463–464
      - quantification, drug concentrations, 460–461
      - rate of absorption, 463–464
    - vs. ex vivo* tissue models, 444–445
    - IPRL models, 445
    - local respiratory diseases treatment, 443–444
    - selection factors
      - airway structure, 447–449
      - biological response, 452–453
      - cells, alveolar region, 449–451
      - drug absorption, 452
      - lung circulation, 451–452
      - morphologic features, pleuras and bronchioles, 448–449
      - respiratory mechanics, 446–447
    - treatments, 465–466
  - IPRL model. *See* Isolated perfused lung (IPRL) model
  - Isolated perfused lung (IPRL) model, 444–445
- J**
- Jet mills. *See* Fluid energy milling technology
  - Jet nebulizers
    - affecting factors, 225–226
    - choice, 227–228
    - design models, 227
    - mechanism, 225
    - particle engineering technologies, 288
    - schematic diagram, 226
    - shortcomings, 227
- L**
- L- $\alpha$ -Dipalmitoyl phosphatidylcholine (DPPC), 277
  - Large porous particles (LPPs), 114, 265, 266
  - Levonorgestrel therapy, 318
  - Lipid-coated budesonide microcrystals, 289
  - Lipoplex. *See* Lipoplex-mediated transfection
  - Lipoplex-mediated transfection, 369
  - Liposome-encapsulated 9-NC (L-9NC) therapy, 325
  - Liposomes
    - availability reasons, 315, 316
    - classification
      - dependent parameters, 314
      - size and lamellarity, 315
    - drug absorption avoidance, 110–111
    - formulating factors
      - BAL, rigidity and stability, 317
      - DPI, 318
      - particle size, 316–317
      - surface charge, 317
    - half-lives, liposome-encapsulated
      - <sup>3</sup>H-terbutaline, 242, 243
    - nebulisation
      - duration, 320
      - factors influencing jet nebulisation, 319
      - vs.* jet and vibrating mesh nebulisers, 319
      - non-extruded small size reduction, 320
      - stealth effect, 321
    - particle size and surface charge, 316–317
    - pharmacokinetics, 240–241
    - phospholipids, chemical structure, 238
    - rate of release, 239
    - vs.* solution formulations, 239–242
    - in vitro*, preclinical and clinical studies
      - cancer, 324–326
      - macrophage targeting, 326–327
      - nucleotide delivery, 329–330
      - PAH, 327
      - peptide and protein delivery, 328–329
      - pulmonary infections treatment, 322–324
  - Lung absorption
    - diffusion control
      - half-life *vs.* lipophilicity, 130–131
      - half-life *vs.* molecular weight, 131–132
    - nonabsorptive clearance, 137–138
    - transporter control
      - ATP-binding cassette (ABC), 133–134
      - BCRP, 133–134
      - endocytotic, 135–137
      - solute-linked carrier (SLC/SLCO), 135
      - uptake transporter, 135

- Lung clearance mechanisms
  - absorption, epithelial cells, 104–105
  - administration methods, healthcare, 101–102
  - alveolar macrophages, 104
  - drug release *vs.* dosage form, 102
  - factors, drug release rate, 102–103, 105
  - metabolic degradation, 105–106
  - mucociliary escalator, 103–104
- Lung disposition
  - absorption *vs.* nonabsorptive clearance, 128–129
  - aerodynamic diameter, 128
- Lung resistance protein (LRP), 429
- M**
- Macrophage clearance avoidance
  - macrophages, 119–120
  - particle shape
    - actin staining, 117
    - schematic diagram, phagocytosis occurrence, 118
  - particle size
    - LPPs and NPs, 114
    - macrophage uptake, 116
    - Trojan particles, 115
    - VMD and cumulative release profiles, 115
  - stealth characteristics, 118–119
- Macrophage targeting, 326–327
- MDI. *See* Metered-dose inhaler (MDI)
- MDLI. *See* Metered dose liquid inhalers (MDLI)
- Metered-dose inhaler (MDI)
  - inhalation drug products, 492–493
  - particle engineering technologies, 289
- Metered dose liquid inhalers (MDLI)
  - AerX® system, 233
  - Aradigm AerX™ aerosol, 232
- Microcrystals
  - controlled release function, 256
  - in vitro* and *in vivo* studies, 257
- Microencapsulation. *See* Drug formulations
- Microparticles
  - composites, 266
  - drug absorption avoidance, 111–112
- Microprecipitation technology, 300
- Milling technology
  - fluid energy, 291–292
  - mechanical process, 291
  - wet, 292
- MRP1 protein, 426–428
- MSLI. *See* Multistage liquid impinger (MSLI)
- Mucociliary clearance
  - avoidance
    - aerodynamic targeting, 106–107
    - extracellular barriers, 107–108
    - schematic diagram, 103
  - pulmonary drugs, 24–27
- Mucociliary escalator
  - aerosol particle transport
    - histology, airway epithelial culture, 149–150
    - mucolytic agents, 150–151
    - physicochemical properties, 151–152
    - schematic diagram, 103
  - lung clearance mechanisms
    - aerodynamic targeting, 106–107
    - schematic diagram, 103
  - nanodisperse microspheres, 351
  - in vivo* animal models, 444
- Mucolytic agents, 150–151
- Mudge inhaler, 54–55
- Multistage cascade impactor, 385
- Multistage liquid impinger (MSLI), 433
- N**
- NanoCluster SN™ process, 306
- NanoEdge™ technology, 293
- Nanoengineered particle, 357–358
- Nanoparticles (NPs)
  - adsorption, distribution, metabolism and excretion (ADME), 336
  - disadvantages, 266
  - drug delivery
    - absorption, 339–341
    - particle deposition *vs.* particle size, 338, 339
    - publications, nanomedicine, 337
  - macrophage clearance avoidance, 114–115
  - pulmonary delivery strategies
    - DPI, 349–355
    - drug encapsulated nanodispersions, 345–347
    - lipid nanoparticles, 347–349
    - nanoscale powders for redispersion, 344–345
    - nebulized dispersions, 341–349
    - stabilized nanodispersions, 342–344
  - toxicology
    - bioerodible nanoparticles, 358–360
    - combustion-derived particles, 356–357
    - nanoengineered particles, 357–358
    - regulatory stance, 358
- NanoPure® technology, 293

- Nanopure XP technology, 293
- Native smoking pipes, 52
- Nebulisation, liposomes
- duration, 320
  - factors influencing jet nebulisation, 319
  - vs. jet and vibrating mesh nebulisers, 319
  - non-extruded small size reduction, 320
  - stealth effect, 321
- Nebulized dispersions, pulmonary delivery
- strategies
  - drawbacks, 349
  - drug encapsulated nanodispersions, 345–347
  - lipid nanoparticles, 347–349
  - nanoscale powders, redispersion, 344–345
  - stabilized nanodispersions, 342–344
- Nebulizers
- advantages, 224
  - aerosolization systems
    - droplet formation, 81–84
    - inhaler technology, 75
    - solution/suspension formulation, 80
    - types, 81  - disadvantage, 224–225
  - jet nebulizer
    - affecting factors, 225–226
    - choice, 227–228
    - design models, 227
    - mechanism, 225
    - schematic diagram, 226
    - shortcomings, 227  - limitations, 224
- MDLI
- AerX® system, 233
  - Aradigm AerX™ aerosol, 232
- optimization, 230–231
- optimizing nebulizer
- AAD system, 231
  - reservoir, 230
- particle engineering technologies, 288
- tobramycin, 224
- ultrasonic nebulizer
- aerosolization, 229
  - design, 228–229
  - developments, 229–230
  - disadvantages, 228
  - piezoelectric crystal, 228
  - schematic diagram, 229
  - uses, 224
- Nelson inhaler, 62
- Nonspecific particle trapping, 35
- Noyes-Whitney equation, 305, 340
- Nucleotide delivery, 329–330
- O**
- OIPs. *See* Orally inhaled drug products (OIPs)
- Oligo(lactic acid) (OLA), 273
- Orally inhaled drug products (OIPs), 531–532
- P**
- Paclitaxel therapy, 324, 325
- PAH. *See* Pulmonary arterial hypertension (PAH)
- Particle engineering technologies
- HFA-based formulations, pMDIs, 188–190
  - high pressure homogenization
    - microfluidizer, 292–293
    - piston-gap, 293–294  - inhaled aerosols
    - DPI, 289–290
    - MDI, 289
    - nebulizer, 288
    - ultrasonic nebulizers, 288–289
    - uses, 288  - mechanisms
    - aerodynamic diameter ( $d_a$ ), 286
    - cascade impactor, 286, 287
    - cunningham correction factor ( $C_c$ ), 287
    - FPF<sub>5</sub>, 288
    - particle deposition, in lungs, 285
- milling
- diagram, 291
  - fluid energy, 291–292
  - wet, 292
- nanoparticle-based formulations
- milling, 306
  - nifedipine nanoparticle cluster, 307
  - Noyes-Whitney equation, 305
  - saturation solubility drugs formulated, 304
  - typically and presumably, 306
- porous microparticle fabrication
- techniques, 303–304
- precipitation technology
- application, 298
  - direct controlled crystallization, 298–299
  - EPAS, 300–301
  - microprecipitation
    - and sono-crystallization, 300
    - spherical agglomerates crystallization, 299–300
- pulmonary physiology, 284
- shape factor, 286

- Particle engineering technologies (*cont.*)
- spray drying technology
    - anti-asthmatic drugs and atomizers types, 294
    - controlled evaporation droplets, 298
    - evaporation, low-boiling-point solutions, 298
    - low density particles, 295
    - péclet number, 296
    - PNAPs, 296, 297
    - process steps, 294, 295
    - PulmoSphere™ process, 295, 296
    - spray freeze drying (SFD), 297
    - supercritical fluid (SCF) technology
      - griseofulvin morphology, 303
      - vs. SAS, 302
      - typical phase diagram, 301
  - Passive diffusion, 31–32
  - Passive DPIs, 205
  - Passive inhalation, 454–457
  - PBPK modeling. *See* Physiologically based pharmacokinetic (PBPK) modeling
  - PEGylation
    - drug absorption avoidance, 113
    - excipient conjugates, 249
    - nanoparticles, 192, 340, 348
  - Peptide and protein delivery, 328–329
  - P-glycoprotein, 431
  - Phagocytosis. *See* Alveolar macrophage clearance
  - Physiologically based pharmacokinetic (PBPK) modeling, 462
  - Piston-gap homogenization, 293–294
  - Plasmid DNA (pDNA)
    - aerosolization, 368–369
    - lipoplexes and polyplexes, 369–372
    - transport into lung
      - intracellular barriers gene therapy, 370, 376
      - studies, overview of, 376
      - in vitro* and *in vivo* immunogenicity, 376
    - vaccination
      - advantages, 373–375
      - vs. gene therapy, 372
      - potential barriers, 373, 374
      - transport into nucleus, 374
  - Plume geometry, inhalation drug products, 504, 515
  - pMDIs. *See* Pressurized metered-dose inhalers (pMDIs)
  - PNAPs. *See* Porous nanoparticle-aggregate particles (PNAPs)
  - Poly(L-lysine) (PLL). *See* Polyplex-mediated transfection
  - Poly(lactic acid) (PLA), 272–273
  - Poly(lactic-co-glycolide acid) (PLGA), 276
  - Poly(vinyl alcohol) (PVA), 273–274
  - Poly(ethylene glycol)–1,3-bis(carboxyphenoxy)propane-sebacic acid (SA) (PEG-CPP-SA), 278, 279
  - Polyethyleneimine (PEI). *See* Polyplex-mediated transfection
  - Poly lactide. *See* Poly(lactic acid) (PLA)
  - Polymer degradation, 266
  - Polymeric nanocarriers (NCs), 192–194
  - Polymers
    - copolymers, 248
      - PBLG-PEO-PBLG, 278
      - PEG-CPP-SA, 278, 279
      - PLA-PEG-PLA, 277, 278
      - poly(lactic-co-glycolide acid) (PLGA), 275–277
    - definition, 243
    - function mechanisms
      - bulk degradation and surface erosion, 268
      - drug delivery, mechanisms of, 266, 267
      - hydrogel swelling, environment changes, 267
    - limitations and safety concerns, 279
    - mechanism, controlled release, 244
    - natural and synthetic types, 243, 245–247
    - natural type
      - albumin, 268
      - carrageenan, 268–269
      - chitosan, 269–270
      - gelatin, 270–271
      - hyaluronic acid (HA), 271–272
    - particle size, 265
    - synthetic type
      - acrylic acid derivatives, 274–275
      - oligo(lactic acid) (OLA)., 273
      - poly(lactic acid) (PLA), 272–273
      - poly(vinyl alcohol) (PVA), 273–274
  - Polymer swelling, 266
  - Polyplex. *See* Polyplex-mediated transfection
  - Polyplex-mediated transfection
    - biodegradable polysaccharides molecular structure, 370
    - chitosan, 370, 372
    - PEI and PLL, 370, 371
  - Poly(g-benzyl-L-glutamate)-poly(ethylene oxide)-poly(g-benzyl-L-glutamate) (PBLG-PEO-PBLG), 278
  - Poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA), 277, 278

- Porous nanoparticle-aggregate particles (PNAPs), 296, 297
- Powder de-agglomeration principles, DPI
  - air classifier technology, 211–212
  - device resistance and flow rate, 214–215
  - mechanical forces, 208–209
  - meshes and screens, 215–216
  - Novolizer™, 212
  - sustained exposure, flow stream, 210–212
  - turbulence inducement, 207–208
  - Twincer™, 212
  - vibration induced dispersion, 212–214
- Powder drug inhalation, 493–494
- Powder formulation
  - drug aerosolization, 91–92
  - drug deposition, 92–94
  - elongated particles, 95
  - low density porous particles, 94
  - mixing, 89–91
  - particulate interactions, 87–89
- Pressurized metered-dose inhalers (pMDIs)
  - aerosolization systems
    - droplet formation, 84–86
    - inhaler technology, 76, 77
    - solution/suspension formulation, 80–81
  - AIM concept, 389–390
  - components
    - commercial HFA, 170, 171
    - hardware, 168–169
    - hydrofluoroalkane (HFA) propellants, 169–170
    - schematic diagram, 169
  - vs. DPI, 204
  - vs. DPIs, 166
  - environmental impact, propellants, 166–167
  - formulation development, 167–168
  - HFA-based formulations
    - cosolvents, 172–173
    - excipients, 172
    - particle technologies, 188–190
    - solubility and solvation, 173–188
    - solubility enhancers, 172–173
    - solute solubility, 174–179
  - nanoparticles, non-polar APIs, 190–191
  - oral inhalation delivery,
    - biomacromolecules, 194–195
  - polymeric nanocarriers (NCs), 192–194
  - regulatory systems
    - factors, 532
    - influencing factors, 532
    - montreal protocol impact, 531
    - patient population size, 531
    - systemic drug delivery, 531–532
- Primary cell cultures
  - alveolar epithelia, 418–419
  - tracheo-bronchial epithelia, 418
- Prodrugs
  - drug absorption avoidance, 113
  - duration of effect, 40
- Product specifications
  - regulatory systems
    - drug product and device requirements, 531–540
    - legacy, pMDIs, 530–532
- Product testing. *See* Product specifications
- Propellant driven metered dose inhalers. *See* Pressurized metered-dose inhalers
- Pulmonary arterial hypertension (PAH), 327
- Pulmonary delivery strategies
  - drug encapsulated nanodispersions
    - cation-induced alginate gelification, 347
    - chemotherapeutic treatment, 345, 346
    - poly(lactic-co-glycolic acid) (PLGA), 346, 347
    - tumor-targeting, 345
  - lipid nanoparticles, 347–349
  - nanoscale powders for redispersion, 344–345
  - nebulized dispersions, 341–342
  - stabilized nanodispersions
    - air-jet and vibrating mesh nebulizers, 343
    - budesonide formulation, 342, 343
    - synthetic or natural surfactants, 342
- Pulmonary drugs
  - absorption
    - assessment, 36–38
    - drug transporters, 32–34
    - importance, lung physiology, 35–36
    - membrane vesicles, 34–35
    - nonspecific particle trapping, 35
    - passive diffusion, 31–32
  - clearance
    - alveolar macrophages, 27
    - mucociliary, 24–27
  - dissolution kinetics, 22–24
  - effect duration
    - biotransformation, 39–40
    - dissolution rate, 38–39
    - formulation strategies, 39
    - prodrugs and soft drugs, 40
    - protein binding, 41
    - tissue affinity, 39
  - metabolism, 27–30
- Pulmonary infections treatment, 322–324
- Pulmonary nebulizer machine. *See* Nebulizers

PulmoSphere™ process, 295, 296  
 PulmoSphere® technology, 354, 355

## R

Radiolabeling aerosols  
 inhalation deposition analysis, 478–480  
 validation process, 479–480  
 Rapid expansion from supercritical to aqueous solution (RESAS), 302  
 Rapid expansion of liquefied-gas solution and homogenization (RELGSH), 302  
 Rapid expansion of supercritical solutions (RESS) atomizes, 301  
 Regulatory systems, product testing  
 drug product and device requirements  
 CMC framework, 532–533  
 features, 533, 535  
 performance targets, 535  
 risk concerns, 536–540  
 systematic analysis, 536  
 inhalation products, 530  
 legacy, pMDIs  
 factors, 532  
 influencing factors, 532  
 montreal protocol impact, 531  
 patient population size, 531  
 systemic drug delivery, 531–532  
 RELGSH. *See* Rapid expansion of liquefied-gas solution and homogenization (RELGSH)  
 RESAS. *See* Rapid expansion from supercritical to aqueous solution (RESAS)  
 Respiratory system  
 airways  
 alveolar cells, 9–10  
 macrostructure and function, 3–4  
 lung absorption  
 diffusion control, 130–132  
 nonabsorptive clearance, 137–138  
 transporter control, 132–137  
 lung disposition, 128–129  
 RESS. *See* Rapid expansion of supercritical solutions (RESS) atomizes  
 Rifampicin, 276  
 Rotahaler, 71

## S

Sales-Girons' portable atomiser, 57–58  
 SAS. *See* Supercritical anti-solvent (SAS)  
 SCF. *See* Supercritical fluid (SCF) technology

SEDS. *See* Solution-enhanced dispersion by supercritical fluids (SEDS)  
 SFD. *See* Spray freeze drying (SFD)  
 SFEE. *See* Supercritical fluid extraction of emulsions (SFEE)  
 Siegle's inhaler, 59  
 Simulated interstitial lung fluid (SILF), 410  
 Simulated surfactant lung fluid (SSLF), 410  
 Single photon emission computed tomography (SPECT), 476, 478, 483  
 Single-stage inertial impactor, 384–385  
 SLC/SLCO. *See* Solute-linked carrier (SLC/SLCO)  
 SLC-transporters, 428–429  
 SLIT. *See* Sustained release lipid inhalation targeting (SLIT)  
 Small interference RNA (siRNA) delivery. *See* Antisense oligodeoxynucleotide (AS-ODN)  
 Solid lipid nanoparticles (SLN), 348  
 Solubility enhancers, 172–173  
 Solute-linked carrier (SLC/SLCO), 135  
 Solution-enhanced dispersion by supercritical fluids (SEDS), 302  
 Solutions and suspensions, inhalation drug products, 495  
 Solutions inhalation, 495  
 Solution/suspension formulation  
 nebulizer, 80  
 pMDI, 80–81  
 Sono-crystallization, 300  
 SPECT. *See* Single photon emission computed tomography (SPECT)  
 Spherical agglomerates crystallization, 299–300  
 Spinhaler, 71  
 Spray drying technology  
 anti-asthmatic drugs and atomizers types, 294  
 droplets, controlled evaporation of, 298  
 low-boiling-point solutions, evaporation of, 298  
 low density particles, 295  
 nanodisperse microspheres, 349, 350  
 pécllet number, 296  
 PNAPs, 296, 297  
 process steps, 294, 295  
 PulmoSphere™ process, 295, 296  
 spray freeze drying (SFD), 297  
 Spray freeze drying (SFD), 297  
 Spray freezing into liquid. *See* Spray freeze drying (SFD)  
 Spray freezing into liquid (SFL) cryogenic technique, 344

- Sprays formulation  
  droplet formation  
    nebulizer, 81–84  
    pMDI, 84–86  
  evaporation, 86  
  inhalation drug products, 495–496  
  solution/suspension formulation  
    nebulizer, 80  
    pMDI, 80–81  
  suspension aerosols aggregation, 86–87
- Stern inhaler, 54
- Supercritical anti-solvent (SAS), 302
- Supercritical fluid extraction of emulsions (SFEE), 302, 303
- Supercritical fluid (SCF) technology, 301–303
- Surface morphology  
  AFM imaging, 398–399  
  light scattering, 399–400
- Surfactant proteins (SPs), 316
- Suspensions  
  aerosols aggregation, 86–87  
  controlled release function, 256  
  inhalation, 495  
  *in situ* study, rat lungs, 258
- Sustained release lipid inhalation targeting (SLIT), 324
- T**
- Technosphere® technology, 354
- Thin film freezing (TFF) technology, 345
- Tracheo-bronchial epithelial cells  
  ABC-transporters, 425–426  
  BEAS-2B cell line, 420–421  
  biopharmaceutical research, 425–430  
  Caco-2 cells, 419–420  
  Calu-3, 420  
  drug permeability, 425  
  lung resistance protein (LRP), 429  
  MRP1 protein, 426–428  
  organic anion transporting polypeptides (OATP), 429  
  primary cell cultures, 418  
  SLC-transporters, 428–429
- Trans epithelial electrical resistance (TEER), 418
- Transferrin receptors (TfR), 325, 326
- TSL. *See* Twin-stage particle impinger (TSI)
- Turbuhaler, 71
- Twin-stage particle impinger (TSI), 433–434
- U**
- Ultrasonic nebulizers  
  aerosolization, 229  
  design, 228–229  
  developments, 229–230  
  disadvantages, 228  
  droplet formation, 81–82  
  particle engineering technologies, 288–289  
  piezoelectric crystal, 228  
  schematic diagram, 229
- V**
- Vasoactive intestinal peptide (VIP), 328
- Vibrating-mesh nebulizer, 82
- VIP. *See* Vasoactive intestinal peptide (VIP)
- VIP self associated with sterically stabilised liposomes (VIP-SSL), 328, 329
- VMD. *See* Volume median diameter (VMD)
- Volume median diameter (VMD), 115
- W**
- Wet milling technology, 292